Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients

NCT01753297 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01753297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01753297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients
Lead sponsor
Ipsen
Phase
Phase 4
Overall status
Completed
Start date
December 11, 2012
Completion date
September 9, 2019
Enrollment
226 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer